Nath Bio-Genes (India) Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 252.97 million compared to INR 216.58 million a year ago. Revenue was INR 252.97 million compared to INR 216.58 million a year ago. Net income was INR 13.49 million compared to INR 28.08 million a year ago. Basic earnings per share from continuing operations was INR 0.71 compared to INR 1.48 a year ago. Diluted earnings per share from continuing operations was INR 0.71 compared to INR 1.48 a year ago.
For the nine months, sales was INR 2,563.76 million compared to INR 2,511.51 million a year ago. Revenue was INR 2,563.76 million compared to INR 2,511.51 million a year ago. Net income was INR 335.75 million compared to INR 489.5 million a year ago. Basic earnings per share from continuing operations was INR 17.67 compared to INR 25.76 a year ago. Diluted earnings per share from continuing operations was INR 17.67 compared to INR 25.76 a year ago.